youtube_live
Q2 2027 earnings • in 4 days
See detailschevron_right
STAR:NSE
Strides Pharma Science Ltd
₹1,039.20
arrow_upward
+2.40%(+24.40) 1D
Oct 26, 11:28:09 AM GMT+5:30 · INR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for STAR...
Open
₹1,006.50
High
₹1,053.90
Low
₹1,001.00
Mkt. cap
95.79B
Avg. vol.
247.02K
Volume
127.27K
Dividend
0.48%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
15.61
52-wk high
₹1,260.90
52-wk low
₹768.65
EPS
₹66.55
Shares outstanding
89.55M
No. of employees
4K
Open
₹1,006.50
High
₹1,053.90
Low
₹1,001.00
Mkt. cap
95.79B
Avg. vol.
247.02K
Volume
127.27K
Dividend
0.48%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
15.61
52-wk high
₹1,260.90
52-wk low
₹768.65
EPS
₹66.55
Shares outstanding
89.55M
No. of employees
4K
News stories
From web sources and news partners
Benzinga
·
8 minutes ago
Stock Market: Will S&P 500 Open Up or Down Today?
Yahoo Finance
·
6 hours ago
Cramer Beat the S&P At His Hedge Fund But Advises Retail to Join The Index
富途牛牛
·
1 day ago
The highlight of earnings season is here: more than one-third of S&P 500 companies will report their results this week.
Traders Union
·
9 hours ago
S&P 500 has averaged 1.9 percent gain in November since 1950, Phil Rosen notes
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.
Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies.
Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3.54K
Founded1990
HeadquartersBengaluru, Karnataka, India
SectorPharmaceutical industry
Websitestrides.com
Next call in 4 days
Fri, Oct 30, 6:30 AM
Fiscal period
Q2 2027
- Normalized EPS / Est. (INR)
- GAAP EPS / Est. (INR)
- / -
Revenue / Est. (INR)
- / 14.15B
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in INR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 12.21B | 11.95B | 13.23B | 12.65B |
Cost of goods sold | 5.15B | 4.63B | 7.19B | 4.95B |
Cost of revenue | 5.15B | 4.63B | 7.19B | 4.95B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.27B | 2.30B | 3.45B | 2.43B |
Operating expense | 5.24B | 5.46B | 4.91B | 5.97B |
Total operating expenses | 10.39B | 10.09B | 12.10B | 10.92B |
Operating income | 1.82B | 1.85B | 1.13B | 1.73B |
Other non operating income | 271.40M | 1.07B | -1.66B | 48.90M |
EBT including unusual items | 1.53B | 2.45B | 1.48B | 2.00B |
EBT excluding unusual items | 1.62B | 2.49B | 502.07M | 1.36B |
Income tax expense | 215.93M | 373.53M | 187.70M | 341.23M |
Effective tax rate | 14.10% | 15.22% | 12.68% | 17.09% |
Other operating expenses | 2.47B | 2.66B | 928.53M | 2.97B |
Net income | 1.28B | 2.02B | 1.27B | 1.57B |
Net profit margin | 10.45% | 16.92% | 9.59% | 12.40% |
Earnings per share | - | - | - | - |
Interest and investment income | - | - | 404.82M | - |
Interest expense | -461.27M | -433.79M | -130.82M | -405.61M |
Net interest expenses | -461.27M | -433.79M | 274.00M | -405.61M |
Depreciation and amortization charges | 496.43M | 506.23M | 532.49M | 563.99M |
EBITDA | 2.31B | 2.25B | 1.55B | 2.15B |
Gain or loss from assets sale | - | - | - | - |